title: [Therapy of pain syndromes in multiple sclerosis -- an overview with evidence-based recommendations].
abstract: While pain is a common problem in multiple sclerosis (MS) patients, it is frequently overlooked and has to be asked for actively. Pain can be classified into 4 diagnostically and therapeutically relevant categories. 1. PAIN DIRECTLY RELATED TO MS: Painful paroxysmal symptoms like trigeminal neuralgia or painful tonic spasms are treated with carbamazepine as first choice, or lamotrigine, gabapentin, oxcarbazepine and other anticonvulsants. Painful "burning" dysaesthesia, the most frequent chronic pain syndrome, are treated with tricyclic antidepressants or carbamazepine, further options include gabapentin or lamotrigine. While escalation therapy may require opioids, the role of cannabinoids in the treatment of pain still has to be determined. 2. PAIN INDIRECTLY RELATED TO MS: Pain related to spasticity often improves with adequate physiotherapy. Drug treatment includes antispastic agents like baclofen or tizanidine, alternatively gabapentin. In severe cases botulinum toxin injections or intrathecal baclofen merit consideration. Physiotherapy and physical therapy may ameliorate malposition-induced joint and muscle pain. Moreover, painful pressure lesions should be avoided using optimally adjusted aids. 3. Treatment-related pain can occur with subcutaneous injections of beta interferons or glatiramer acetate and may be reduced by optimizing the injection technique and by local cooling. Systemic side effects of interferons like myalgias can be reduced by paracetamol or ibuprofen. 4. Pain unrelated to MS such as back pain or headache are frequent in MS patients and may be worsened by the disease. Treatment should be follow established guidelines. In summary, a careful analysis of the pain syndrome will allow the design of the appropriate treatment plan using various medical and non-medical options and thus will help to ameliorate the patients' quality of life.
authors.affiliation: Marianne Strauss-Klinik, Berg. walter.poellmann@ms-klinik.info
authors.forename: W
authors.initials: W
authors.lastname: Pöllmann
authors.forename: W
authors.initials: W
authors.lastname: Feneberg
authors.forename: A
authors.initials: A
authors.lastname: Steinbrecher
authors.forename: M R
authors.initials: MR
authors.lastname: Haupts
authors.forename: T
authors.initials: T
authors.lastname: Henze
mesh_terms: D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications*; D009437:Neuralgia / Q000188:drug therapy / Q000209:etiology; D010146:Pain / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology*